NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a
biotechnology company focused on discovering and developing
transformative therapeutics for patients, today announced that
abstracts related to all three of the company’s myeloid
reprogramming and checkpoint inhibition programs have been accepted
for presentation at the American Association for Cancer Research
(AACR) Annual Meeting, which will take place April 8 – 13, 2022 at
the Ernest N. Morial Convention Center in New Orleans, LA.
The four receptors targeted by NGM Bio’s myeloid reprogramming
and checkpoint inhibition portfolio – ILT2, ILT4, ILT3 and LAIR1 –
belong to the LILR family, which may play a central role in
establishing an immune-suppressive state in the tumor
microenvironment. All three programs in this NGM Bio-discovered,
wholly-owned portfolio – NGM707 (a dual ILT2/ILT4 antagonist
antibody product candidate), NGM831 (an ILT3 antagonist antibody
product candidate), and NGM438 (a LAIR1 antagonist antibody product
candidate) – are engineered to target various LIR suppressive
receptors with the goal of releasing myeloid checkpoints and
reprogramming myeloid cells to enhance anti-tumor immunity. For
more details on NGM Bio’s oncology portfolio visit NGM Bio’s
website at https://www.ngmbio.com/discovery-engine/oncology/.
“Our extensive research efforts focused on tumor stroma biology
and myeloid reprogramming have yielded important new insights on
the potential to shift myeloid cells from a suppressive state to a
stimulatory state to promote antitumor immunity,” said Dan Kaplan,
Ph.D., Head of Translational Immune-Oncology at NGM Bio. “This work
also showcases the advantage of our in-house discovery engine,
which seamlessly integrates deep biological interrogation with
protein and antibody engineering to yield potentially life-changing
medicines. We’re delighted to share preclinical research
underpinning NGM707, NGM831 and NGM438 at the upcoming AACR annual
meeting, as we continue our efforts to advance myeloid checkpoint
inhibition as a new frontier in immuno-oncology.”
Oral Presentation at 2022 AACR Annual
Meeting
Abstract
title: |
Immune
inhibitory receptors ILT2 and ILT4 exhibit both distinct and
overlapping biology in vitro and in vivo |
Session title: |
Immune Checkpoint and Immune Modulatory Therapy |
Abstract #: |
664 |
Location: |
Immune Checkpoint and Immune Modulatory Therapy Minisymposium
Session, April 10 3:00 – 5:00 PM |
Both ILT2 and ILT4 are highly expressed on tumor-infiltrating
myeloid cells, while ILT2 is also expressed on T cells and natural
killer (NK) cells. NGM Bio conducted research to explore the
relative contribution of ILT2 and ILT4 on in vitro immune
activation and in vivo anti-tumor activity, using both
mono-specific ILT2 and ILT4 antagonist antibodies and the ILT2/ILT4
dual antagonist NGM707.
Despite high expression of ILT2 and ILT4 on myeloid cells,
evidence from standard in vitro assays suggested that ILT2 and ILT4
have distinct functional activities. NGM Bio’s research
demonstrated that both ILT2 and ILT4 play key roles in myeloid
immune suppression and showed that blockade of these two receptors
can have an additive or synergistic effect. The research also
demonstrated that ILT2 blockade may further enhance T cell and NK
cell function. Additionally, the researchers used humanized mouse
models to characterize the in vivo anti-tumor activity of ILT2 and
ILT4 blockade. Consistent with their in vitro findings, the
researchers observed a distinct effect of ILT2 and ILT4 blockade on
tumor growth inhibition and demonstrated that blockade of ILT2 and
ILT4 may be complementary to PD-1 inhibition. These data support
the clinical evaluation of NGM707 alone and in combination with
PD-1 blockade.
A Phase 1/2 study evaluating the potential of NGM707 in patients
with advanced solid tumors with elevated expression of ILT2 and
ILT4 as a monotherapy and in combination with KEYTRUDA®
(pembrolizumab) is underway. NGM Bio anticipates enrolling
approximately 180 patients in the study. An initial data readout
from the Phase 1a portion (monotherapy dose escalation) of the
trial is expected in the second half of 2022.
Late-Breaking Poster Presentations at 2022 AACR Annual
Meeting
Abstract
title: |
Preclinical
characterization of NGM831, an ILT3 antagonist antibody for the
treatment of solid tumors |
Abstract #: |
7874 |
Location: |
Poster Session 18, Late-Breaking Research: Immunology 2, April
13 2022, 9:00 AM – 12:30 PM |
|
|
Abstract title: |
Preclinical development of NGM438, a novel anti-LAIR1
antagonist monoclonal antibody for the treatment of collagen-rich
solid tumors |
Abstract #: |
219 |
Location: |
Poster Session 18, Late-Breaking Research: Immunology 2, April
13 2022, 9:00 AM – 12:30 PM |
Late-breaking abstract text will be available on Friday, April 8
at 1:00 p.m. ET, per AACR guidance. NGM Bio plans to announce
details on these poster presentations in alignment with AACR’s
embargo policy.
KEYTRUDA® is a registered trademark of Merck Sharp &
Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ,
USA.
Abbreviations (in Alphabetical Order)
ILT2=Immunoglobin-Like Transcript 2; ILT3=Immunoglobin-Like
Transcript 3; ILT4=Immunoglobin-Like Transcript 4; LILR=Leukocyte
Immunoglobin-Like Receptor [ILT2 = LILRB1, ILT3=LILRB4,
ILT4=LILRB2]; LIR=Leukocyte Immunoglobin-Like Receptor;
LAIR1=Leukocyte-Associated Immunoglobulin-Like Receptor 1.
About NGM Bio
NGM Bio is focused on discovering and developing novel,
life-changing medicines for people whose health and lives have been
disrupted by disease. The company’s biology-centric drug discovery
approach aims
to seamlessly integrate interrogation of complex
disease-associated biology and protein engineering expertise to
unlock proprietary insights that are leveraged to generate
promising product candidates and enable their rapid advancement
into proof-of-concept studies. As explorers on the frontier of
life-changing science, NGM Bio aspires to operate one of the most
productive research and development engines in the
biopharmaceutical industry. All therapeutic candidates in the NGM
Bio pipeline have been generated by its in-house discovery engine,
with a disease-agnostic mindset, always led by biology and
motivated by unmet patient need. Today, the company has seven
disclosed programs, including four in Phase 2 or 2b
studies, across three therapeutic areas:
cancer, retinal diseases and liver and
metabolic diseases. Visit us at www.ngmbio.com for more
information.
Forward Looking Statements Statements contained
in this press release regarding matters that are not historical
facts are “forward-looking statements” within the meaning of the
Private Securities Litigation Reform Act of 1995. Words such as
“will,” “may,” “expected,” “anticipates,” “preliminary,” “enable,”
“believed,” “designed,” “engineered to,” “suggesting,” “suggest,”
“look forward,” “see,” “potentially,” “potential,” “promise,”
“goal,” “planned,” “plans,” “aspire,” “aim,” “advance” and similar
expressions (as well as other words or expressions referencing
future events, conditions or circumstances) are intended to
identify forward-looking statements. These statements include those
related to: NGM Bio’s product candidates, including the potential
of NGM Bio’s oncology product candidates, NGM07, NGM831 and NGM438,
to release myeloid checkpoints and reprogram myeloid cells to
reverse immune suppression and enhance immune response in tumors;
NGM Bio’s efforts to continue to advance myeloid checkpoint
inhibition as a new frontier in immuno-oncology; the ability to
enroll patients in and the availability and anticipated timing of
data from the Phase 1a study of NGM707; the planned commencement of
Phase 1 clinical trials of NGM831 and NGM438 and the anticipated
timings thereof; and other statements that are not historical fact.
Because such statements deal with future events and are based on
NGM Bio’s current expectations, they are subject to various risks
and uncertainties, and actual results, performance or achievements
of NGM Bio could differ materially from those described in or
implied by the statements in this press release. These
forward-looking statements are subject to risks and uncertainties,
including, without limitation, risks and uncertainties associated
with the costly and time-consuming pharmaceutical product
development process and the uncertainty of clinical success,
including risks related to failure or delays in successfully
initiating, enrolling, reporting data from or completing clinical
studies, as well as the risks that results obtained in clinical
trials to date may not be indicative of results obtained in ongoing
or future trials and that NGM Bio’s product candidates may
otherwise not be tolerable and effective treatments in their
planned indications; NGM Bio’s ability to maintain its amended
collaboration with Merck, including the risk that if Merck were to
breach or terminate the amended collaboration or Merck’s
development funding obligations, NGM Bio would not obtain all of
the anticipated financial and other benefits of the amended
collaboration, and the development and/or commercialization of NGM
Bio’s product candidates within the scope of the amended
collaboration could be delayed, perhaps substantially; the ongoing
COVID-19 pandemic, which has adversely affected, and could
materially and adversely affect in the future, NGM Bio’s business
and operations, including NGM Bio’s ability to timely supply,
initiate, enroll and complete its ongoing and future clinical
trials; the time-consuming and uncertain regulatory approval
process; NGM Bio’s reliance on third-party manufacturers for its
product candidates and the risks inherent in manufacturing and
testing pharmaceutical products; the sufficiency of NGM Bio’s cash
resources, including to fund its wholly-owned programs, and NGM
Bio’s need for additional capital; and other risks and
uncertainties affecting NGM Bio and its development programs,
including those discussed in the section titled “Risk Factors” in
NGM Bio’s annual report on Form 10-K for the year ended December
31, 2021 filed with the United States Securities and Exchange
Commission (SEC) on March 1, 2021 and future filings and reports
that NGM Bio makes from time to time with the SEC. Except as
required by law, NGM Bio assumes no obligation to update these
forward-looking statements, or to update the reasons if actual
results differ materially from those anticipated in the
forward-looking statements.
Investor
Contact:Brian Schoelkopfir@ngmbio.com |
Media
Contact:media@ngmbio.com |
NGM Biopharmaceuticals (NASDAQ:NGM)
Historical Stock Chart
From Sep 2024 to Oct 2024
NGM Biopharmaceuticals (NASDAQ:NGM)
Historical Stock Chart
From Oct 2023 to Oct 2024